If you've been researching weight loss or diabetes treatment in South Africa, you've almost certainly come across names like Ozempic, Wegovy, and Mounjaro. These belong to a class of medications called GLP-1 receptor agonists — and they've become some of the most talked-about drugs in the world.
But what's actually available here? What can you legally get with a prescription? And what should you watch out for? Here's everything you need to know about GLP-1 medications in South Africa right now.
What Are GLP-1 Medications?
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces in the gut after eating. It plays a key role in regulating blood sugar, slowing digestion, and signalling fullness to your brain.
GLP-1 receptor agonists are injectable medications that mimic this hormone. They were originally developed to treat type 2 diabetes, but clinical trials revealed significant weight loss benefits — and that's where the global conversation exploded.
Which GLP-1 Medications Are Registered in South Africa?
The South African Health Products Regulatory Authority (SAHPRA) has approved several GLP-1 medications for use in the country. Here's what's currently available:
Ozempic (semaglutide) — Registered for type 2 diabetes. Administered as a once-weekly injection. Ozempic is the most well-known GLP-1 in South Africa and is widely prescribed off-label for weight management. Monthly costs typically range from R1,700 to R3,200 depending on the dose.
Wegovy (semaglutide) — Contains the same active ingredient as Ozempic but is specifically registered for weight management. Novo Nordisk launched Wegovy in South Africa in 2025, making it the first GLP-1 formally approved here for weight loss at higher therapeutic doses.
Mounjaro (tirzepatide) — A dual GIP/GLP-1 receptor agonist from Eli Lilly, marketed in South Africa by Aspen Pharmacare. Initially launched for type 2 diabetes in December 2024, Mounjaro received SAHPRA approval for weight management in October 2025. It has rapidly become one of the highest-selling pharmaceutical products in the country.
Saxenda (liraglutide) — A daily injectable that was the first GLP-1 registered in South Africa specifically for weight loss. Effective, but the daily dosing schedule and higher monthly cost (around R4,500–R5,000) have made it less popular than weekly alternatives.
Victoza (liraglutide) — The diabetes-focused version of Saxenda. Still available but Novo Nordisk is gradually reducing production in some markets as newer products take over.
Trulicity (dulaglutide) — Another weekly injectable registered for type 2 diabetes.
Soliqua (lixisenatide + insulin glargine) — A combination product used for diabetes management.
What About Oral GLP-1 Options?
An oral tablet form of semaglutide (called Rybelsus) has been registered by SAHPRA but is not yet commercially available in South Africa. Oral GLP-1 pills have been approved in the United States, and when they eventually launch locally, they'll offer an alternative for people who prefer not to inject.
For now, all GLP-1 medications available in South Africa are administered as injections.
The Black Market Problem
SAHPRA has issued repeated warnings about unregistered, compounded, and counterfeit GLP-1 products being sold through social media, WhatsApp groups, gyms, and beauty salons. These products may contain incorrect doses, undisclosed ingredients, or no active ingredient at all.
Both semaglutide and tirzepatide are still under patent in South Africa. Any company importing these active ingredients or manufacturing copies without authorisation is operating illegally.
If you're considering GLP-1 treatment, only purchase from a licensed pharmacy with a valid prescription from a registered medical practitioner. It's the only way to ensure you're getting a safe, SAHPRA-approved product.
How Much Do GLP-1 Medications Cost?
Costs vary significantly by product and dose:
- Ozempic: R1,700–R3,200/month
- Wegovy: R3,000–R6,000/month (dose-dependent)
- Mounjaro: R3,000–R6,000/month (dose-dependent)
- Saxenda: R4,500–R5,000/month
Medical aid coverage for GLP-1 medications remains limited. Most schemes will cover them for type 2 diabetes under certain clinical criteria, but obesity is not recognised as a prescribed minimum benefit (PMB), so weight management use is rarely funded from chronic benefits.
How to Get Started Safely
GLP-1 medications are Schedule 4 prescription medicines in South Africa. The process is straightforward:
- Consult a doctor — either in person or through a legitimate telehealth service
- Get assessed — your doctor will review your medical history, current health, and treatment goals
- Receive a prescription — if appropriate, your doctor will prescribe a specific GLP-1 and starting dose
- Fill at a licensed pharmacy — major chains like Clicks, Dis-Chem, and Medirite stock these medications
Medical supervision isn't just a legal requirement — it's genuinely important. Structured follow-up, proper dose titration, and monitoring for side effects lead to better outcomes and safer treatment.
What's Coming Next?
Generic semaglutide is expected to become available globally as key patents expire, with some analysts projecting availability in South Africa by 2027. This could significantly reduce costs and improve access. Oral formulations are also on the horizon locally, which will make treatment more convenient for many patients.
The GLP-1 landscape in South Africa is evolving rapidly. The most important thing is to access these medications safely, through proper medical channels, with ongoing professional support.